News | February 18, 2020

Proscia Expands Into International Digital Pathology Market To Help Diagnostic Laboratories Keep Pace With Rising Cancer Burden

PHILADELPHIA--(BUSINESS WIRE)--

Proscia, a leading provider of artificial intelligence (AI) enabled digital pathology solutions, has expanded into the international diagnostic pathology market to meet the growing needs of laboratories and cancer patients worldwide. The company has added the leadership of Arun Ananthapadmanabhan as Executive Vice President, Global Growth, to manage commercial operations for its international market. Proscia’s accelerated global focus follows the company’s November announcement that it received CE Mark for its Concentriq® Dx solution for use in primary diagnosis.*

Digital pathology has experienced broad adoption in international markets, where the regulatory landscape and a severely declining pathologist population have encouraged laboratories to implement image-based workflows. These laboratories are realizing the benefits of digitization, including improved efficiency and productivity. A notable example of successful digitization is Spain’s Granada University Hospitals, where pathologists have signed out, on average, 21% more cases each year since implementing a full digital pathology program for primary diagnosis. Digital laboratories are now poised to adopt AI-based computational applications, which will further enhance efficiency and expand the breadth of critical diagnostic information available to improve patient outcomes.

“The European digital pathology market is demonstrating tremendous potential in the face of critical challenges,” said Steve Holloway, Company Director & Principal Analyst at Signify Research. “In a recent workforce census conducted by the Royal College of Pathologists, only three percent of UK pathology departments reported having enough staff to meet clinical demand. Shortages like these are being blamed for ultimately delaying cancer treatment, and the continued adoption of digital pathology and use of artificial intelligence will play a major part in addressing these issues.”

Proscia’s Concentriq digital pathology platform operates at the center of the modern, image-based laboratory. Its end-to-end capabilities include automation of time consuming and error-prone manual tasks, streamlined collaboration, and delivery of deeper operational insights into the hands of laboratory managers. Concentriq is an open, flexible platform that works with any scanner and laboratory information system (LIS), offering seamless integrations with Philips, Leica, 3DHISTECH, Roche, and Hamamatsu among other leading whole slide image scanners. It also serves as a launchpad for the company’s suite of AI applications, enabling laboratories to easily deploy AI in practice.

“With the only AI-enabled digital pathology platform, Proscia is uniquely positioned to enter the international market,” said David West, CEO of Proscia. “This market is primed for the adoption of digital pathology and artificial intelligence, which we can deliver today. We look forward to building upon our traction in the U.S. and working with our growing partner ecosystem to help laboratories worldwide realize the full promise of digital pathology. We’re pleased to welcome Arun to our leadership team to help us carry out this effort with his deep market expertise.”

Arun Ananthapadmanabhan joins Proscia as Executive Vice President, Global Growth, to oversee the company’s international operations. He comes to Proscia from Philips, where he created and led the Computational Pathology business. In addition to strong product and market expertise, Arun brings experience advising on growth strategies from his time as management consultant at Bain. Arun is located in Amsterdam, from where he will be building a team to support his efforts.

“I am excited to join Proscia and advance the company’s mission of perfecting cancer diagnosis with intelligent software,” said Arun Ananthapadmanabhan, Proscia’s Executive Vice President, Global Growth. “There are clear synergies between Proscia’s approach to digital and computational pathology and the needs of the international market. Concentriq is a truly open and reliable platform with embedded, future-proof AI workflows. This is a clear unmet need in the market today that can accelerate the adoption of digital pathology. I am passionate about improving the lives of cancer patients and see a real opportunity to do so as part of the Proscia team.”

About Proscia
Proscia is an AI software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq digital pathology platform and pipeline of AI algorithms, laboratories are leveraging new kinds of data to improve patient outcomes and accelerate discoveries. Proscia’s team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision care. For more information, visit proscia.com.

*In the U.S., Concentriq Dx is not cleared by the FDA for use in primary diagnosis.


Copyright Business Wire 2020